ECSP056027A - Tratar desorden inmunológico usando agonistas de interleucina - 21/receptor de interleucina - 21. - Google Patents
Tratar desorden inmunológico usando agonistas de interleucina - 21/receptor de interleucina - 21.Info
- Publication number
- ECSP056027A ECSP056027A EC2005006027A ECSP056027A ECSP056027A EC SP056027 A ECSP056027 A EC SP056027A EC 2005006027 A EC2005006027 A EC 2005006027A EC SP056027 A ECSP056027 A EC SP056027A EC SP056027 A ECSP056027 A EC SP056027A
- Authority
- EC
- Ecuador
- Prior art keywords
- interleucine
- agonists
- receiver
- immune disorder
- treat immune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Métodos y composiciones para modular la actividad (MU-1) de la interleucina-21 (IL-21)/ receptor de IL-21 usando agonistas IL-21 o receptor IL-21 ("IL-21R" o "MU-1"), se describen. Los agonistas IL-21/ IL-21R pueden ser usados por ellos mismos o en combinación con cinco agentes anti inflamatorios para tratar, por ejemplo, mejorar, síntomas asociados con desordenes inmunológicos del sistema nervioso, por ejemplo esclerosis múltiple.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45692003P | 2003-03-21 | 2003-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP056027A true ECSP056027A (es) | 2006-09-18 |
Family
ID=33098171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005006027A ECSP056027A (es) | 2003-03-21 | 2005-09-20 | Tratar desorden inmunológico usando agonistas de interleucina - 21/receptor de interleucina - 21. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20060159655A1 (es) |
EP (1) | EP1608315A4 (es) |
JP (1) | JP2006523682A (es) |
KR (1) | KR20060015482A (es) |
CN (1) | CN1849131A (es) |
AU (1) | AU2004224277A1 (es) |
BR (1) | BRPI0408523A (es) |
CA (1) | CA2518854A1 (es) |
CO (1) | CO5611161A2 (es) |
CR (1) | CR7994A (es) |
EC (1) | ECSP056027A (es) |
IL (1) | IL198102A0 (es) |
MX (1) | MXPA05010035A (es) |
NO (1) | NO20054343L (es) |
RU (1) | RU2005132458A (es) |
WO (1) | WO2004084835A2 (es) |
ZA (1) | ZA200507235B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
US7314623B2 (en) * | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
DE602004025332D1 (de) | 2003-03-14 | 2010-03-18 | Wyeth Corp | Antikörper gegen il21-rezeptor und deren verwendung |
WO2005030196A2 (en) * | 2003-09-25 | 2005-04-07 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
US20060228331A1 (en) | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
US20060024268A1 (en) * | 2004-05-19 | 2006-02-02 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
EP1773394A2 (en) * | 2004-08-05 | 2007-04-18 | Wyeth a Corporation of the State of Delaware | Antagonizing interleukin-21 receptor activity |
GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
EP2360181B1 (en) * | 2005-04-18 | 2013-09-18 | Novo Nordisk A/S | IL-21 variants |
AU2006340750B2 (en) | 2005-11-28 | 2013-03-07 | Zymogenetics, Inc. | IL-21 antagonists |
US7592427B2 (en) * | 2005-11-28 | 2009-09-22 | Zymogenetics, Inc. | Antibodies to IL-21 receptor |
RU2504552C2 (ru) | 2007-12-07 | 2014-01-20 | Займодженетикс, Инк. | Моноклональные антитела против il-21 человека |
WO2009100035A2 (en) * | 2008-02-01 | 2009-08-13 | Wyeth | Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) |
CA2725154A1 (en) | 2008-05-23 | 2009-11-26 | Wyeth Llc | Methods of treatment utilizing binding proteins of the interleukin-21 receptor |
AR071885A1 (es) | 2008-05-23 | 2010-07-21 | Wyeth Corp | Proteinas de union al receptor de interleuquina 21 |
CA2739357A1 (en) | 2008-09-23 | 2010-04-08 | Wyeth Llc | Methods for predicting production of activating signals by cross-linked binding proteins |
CA2740077A1 (en) * | 2008-10-08 | 2010-04-15 | Cambridge Enterprise Limited | Methods and compositions for diagnosis and treatment |
AU2011258171B2 (en) * | 2010-05-26 | 2016-11-24 | Selecta Biosciences, Inc. | Synthetic nanocarrier combination vaccines |
WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
AU2012207456C1 (en) | 2011-01-18 | 2017-05-04 | Bioniz Therapeutics, Inc. | Compositions and methods for modulating gamma-c-cytokine activity |
US9592288B2 (en) * | 2011-02-18 | 2017-03-14 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
KR102370727B1 (ko) | 2015-10-09 | 2022-03-04 | 바이오니즈, 엘엘씨 | 감마-c-사이토카인의 활성을 저해하는 합성 펩타이드 및 이를 이용한 키트 |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
WO2020009437A1 (ko) * | 2018-07-04 | 2020-01-09 | 서울대학교산학협력단 | 신경손상의 면역세포치료 |
JP7397874B2 (ja) | 2018-08-30 | 2023-12-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
CA3108951A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
AU2019328567A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
EP3987010A1 (en) | 2019-06-21 | 2022-04-27 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
CA3184756A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010025022A1 (en) * | 1997-11-26 | 2001-09-27 | Kikly Kristine Kay | Hnovilr |
US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
WO1999061617A1 (en) * | 1998-05-29 | 1999-12-02 | Human Genome Sciences, Inc. | Interleukins-21 and 22 |
WO2000008152A1 (en) * | 1998-08-04 | 2000-02-17 | Regeneron Pharmaceuticals, Inc. | Novel orphan cytokine receptors |
US6576744B1 (en) * | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
US20020090680A1 (en) * | 1999-05-18 | 2002-07-11 | Millennium Pharmaceuticals, Inc. | Novel IL-9/IL-2 receptor-like molecules and uses thereof |
CA2420992C (en) * | 2000-04-05 | 2010-07-13 | Zymogenetics, Inc. | Soluble zalpha11 cytokine receptors |
WO2003028630A2 (en) * | 2001-10-04 | 2003-04-10 | Genetics Institute Llc. | Methods and compositions for modulating interleukin-21 receptor activity |
ES2334338T3 (es) * | 2001-11-05 | 2010-03-09 | Zymogenetics, Inc. | Antagonistas de il-21. |
US20050063947A1 (en) * | 2002-03-27 | 2005-03-24 | Patrick Hwu | Method for treating cancer in humans |
US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
US20040009150A1 (en) * | 2002-06-07 | 2004-01-15 | Nelson Andrew J. | Methods of treating cancer using IL-21 |
US7314623B2 (en) * | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
DE602004025332D1 (de) * | 2003-03-14 | 2010-03-18 | Wyeth Corp | Antikörper gegen il21-rezeptor und deren verwendung |
US20060024268A1 (en) * | 2004-05-19 | 2006-02-02 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
EP1773394A2 (en) * | 2004-08-05 | 2007-04-18 | Wyeth a Corporation of the State of Delaware | Antagonizing interleukin-21 receptor activity |
US7533965B2 (en) * | 2005-03-07 | 2009-05-19 | Eastman Kodak Company | Apparatus and method for electrostatically charging fluid drops |
GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis |
-
2004
- 2004-03-22 AU AU2004224277A patent/AU2004224277A1/en not_active Abandoned
- 2004-03-22 CN CNA2004800076306A patent/CN1849131A/zh active Pending
- 2004-03-22 RU RU2005132458/13A patent/RU2005132458A/ru unknown
- 2004-03-22 KR KR1020057017652A patent/KR20060015482A/ko not_active Application Discontinuation
- 2004-03-22 MX MXPA05010035A patent/MXPA05010035A/es unknown
- 2004-03-22 JP JP2006507478A patent/JP2006523682A/ja active Pending
- 2004-03-22 ZA ZA200507235A patent/ZA200507235B/en unknown
- 2004-03-22 EP EP04758055A patent/EP1608315A4/en not_active Withdrawn
- 2004-03-22 BR BRPI0408523-0A patent/BRPI0408523A/pt not_active IP Right Cessation
- 2004-03-22 WO PCT/US2004/008833 patent/WO2004084835A2/en active Application Filing
- 2004-03-22 US US10/806,611 patent/US20060159655A1/en not_active Abandoned
- 2004-03-22 CA CA002518854A patent/CA2518854A1/en not_active Abandoned
-
2005
- 2005-09-16 CR CR7994A patent/CR7994A/es not_active Application Discontinuation
- 2005-09-20 EC EC2005006027A patent/ECSP056027A/es unknown
- 2005-09-20 NO NO20054343A patent/NO20054343L/no not_active Application Discontinuation
- 2005-09-21 CO CO05095726A patent/CO5611161A2/es unknown
-
2009
- 2009-04-07 IL IL198102A patent/IL198102A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1849131A (zh) | 2006-10-18 |
NO20054343L (no) | 2005-11-24 |
CO5611161A2 (es) | 2006-02-28 |
RU2005132458A (ru) | 2006-03-20 |
WO2004084835A3 (en) | 2006-05-26 |
MXPA05010035A (es) | 2005-11-17 |
AU2004224277A1 (en) | 2004-10-07 |
IL198102A0 (en) | 2009-12-24 |
CR7994A (es) | 2006-10-17 |
JP2006523682A (ja) | 2006-10-19 |
CA2518854A1 (en) | 2004-10-07 |
WO2004084835A2 (en) | 2004-10-07 |
EP1608315A2 (en) | 2005-12-28 |
KR20060015482A (ko) | 2006-02-17 |
NO20054343D0 (no) | 2005-09-20 |
BRPI0408523A (pt) | 2006-03-21 |
EP1608315A4 (en) | 2008-07-16 |
US20060159655A1 (en) | 2006-07-20 |
ZA200507235B (en) | 2007-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR7994A (es) | Tratar desorden inmunologico usando agonistas de interleucina -21/receptor de interleucina -21 | |
CR8891A (es) | Antagonismo de la actividad del receptor de interleuquina 21 | |
Sattler et al. | Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation | |
TW200531679A (en) | Methods of modulating cytokine activity; related reagents | |
BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
Li et al. | Human umbilical cord-derived mesenchymal stem cells downregulate inflammatory responses by shifting the Treg/Th17 profile in experimental colitis | |
FR13C0062I2 (fr) | Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques | |
ZA200606844B (en) | Use for interleukin-33 (IL33) and the IL-33 receptor complex | |
Gyülvészi et al. | IL‐23‐driven encephalo‐tropism and Th17 polarization during CNS‐inflammation in vivo | |
AR034746A1 (es) | Combinaciones para el tratamiento de trastornos inflamatorios | |
FI963101A (fi) | Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut | |
ECSP077421A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1 | |
NO20072558L (no) | Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav | |
DK0411668T4 (da) | Central-chlolecystokinin-antagonister til behandling af psykiske forstyrrelser | |
DK1899334T3 (da) | Naphthyridinforbindelser | |
DE60313004D1 (de) | Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination | |
Ambrosini et al. | IL‐1β inhibits ILC3 while favoring NK‐cell maturation of umbilical cord blood CD34+ precursors | |
BRPI0411176A (pt) | combinação farmacêutica consistindo de modafinil e outra droga | |
DK0952772T3 (da) | Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration | |
Simberlund et al. | Mesenchymal stem cells in autism spectrum and neurodevelopmental disorders: pitfalls and potential promises | |
AR039803A1 (es) | Proteinas 1 y 2 relacionadas con el receptor ldl y tratamiento de los trastornos de huesos o cartilago | |
NO20056089L (no) | Glykosaminoglykaner for behandling av emosjonelle dysfunksjoner | |
BR9907170A (pt) | Composições farmacêuticas e métodos para uso | |
ATE468130T1 (de) | Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie | |
AR026768A1 (es) | Moleculas similares a antagonistas de receptores de interleukin-1 y usos de las mismas |